Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 9
1978 9
1979 12
1980 20
1981 23
1982 34
1983 50
1984 57
1985 41
1986 45
1987 44
1988 40
1989 60
1990 59
1991 57
1992 47
1993 70
1994 83
1995 87
1996 93
1997 117
1998 117
1999 143
2000 151
2001 176
2002 195
2003 185
2004 207
2005 220
2006 210
2007 181
2008 168
2009 191
2010 173
2011 198
2012 184
2013 144
2014 152
2015 148
2016 180
2017 168
2018 152
2019 190
2020 185
2021 174
2022 191
2023 164
2024 77

Text availability

Article attribute

Article type

Publication date

Search Results

5,214 results

Results by year

Filters applied: . Clear all
Page 1
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN, Carvajal RD. Chen LN, et al. Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027. doi: 10.1080/14737140.2022.2124971. Epub 2022 Sep 19. Expert Rev Anticancer Ther. 2022. PMID: 36102132 Free PMC article. Review.
EXPERT OPINION: Tebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the preferred frontline agent for most HLA-A*0201 positive patients. However, patients with rapidly progressing disease or high tumor benefit may not deriv …
EXPERT OPINION: Tebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the preferred frontline agent …
Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study.
Manca MA, Simula ER, Cossu D, Solinas T, Madonia M, Cusano R, Sechi LA. Manca MA, et al. Int J Mol Sci. 2023 Oct 20;24(20):15398. doi: 10.3390/ijms242015398. Int J Mol Sci. 2023. PMID: 37895076 Free PMC article.
The major histocompatibility complex (MHC) loci, the most polymorphic regions within the human genome, encode protein complexes responsible for antigen presentation and CD4+ and CD8+ cell activation. In prostate cancer (PCa), the second most diagnosed cancer in the …
The major histocompatibility complex (MHC) loci, the most polymorphic regions within the human genome, encode protein complexes responsible …
HLA-A and breast cancer in West Peninsular Malaysia.
Leong PP, Muhammad R, Ibrahim N, Cheong SK, Seow HF. Leong PP, et al. Med Oncol. 2011 Mar;28(1):51-6. doi: 10.1007/s12032-009-9414-6. Epub 2010 Jan 13. Med Oncol. 2011. PMID: 20069393
Breast cancer is the most common malignancy among females in Malaysia. Attempts have been made to investigate the association between breast cancer and human leukocyte antigen (HLA) types. ...The aim of this study is to investigate the association between HLA …
Breast cancer is the most common malignancy among females in Malaysia. Attempts have been made to investigate the association between …
Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy.
Xiong C, Huang L, Kou H, Wang C, Zeng X, Sun H, Liu S, Wu B, Li J, Wang X, Wang Z, Chen L. Xiong C, et al. J Immunother Cancer. 2022 Sep;10(9):e004790. doi: 10.1136/jitc-2022-004790. J Immunother Cancer. 2022. PMID: 36180070 Free PMC article.
BACKGROUND: E6 and E7 oncoproteins are considered ideal antigens of T cell therapy for human papillomavirus (HPV)-related cancers. ...In addition, TTL and IVC-specific TCR-T cells also recognized and killed HPV16(+) patient-derived organoids. CONCLUSIONS: The HLA …
BACKGROUND: E6 and E7 oncoproteins are considered ideal antigens of T cell therapy for human papillomavirus (HPV)-related cancers …
A simple approach for detecting HLA-A*02 alleles in archival formalin-fixed paraffin-embedded tissue samples and an application example for studying cancer immunoediting.
Witt J, Haupt S, Ahadova A, Bohaumilitzky L, Fuchs V, Ballhausen A, Przybilla MJ, Jendrusch M, Seppälä TT, Fürst D, Walle T, Busch E, Haag GM, Hüneburg R, Nattermann J, von Knebel Doeberitz M, Heuveline V, Kloor M. Witt J, et al. HLA. 2023 Jan;101(1):24-33. doi: 10.1111/tan.14846. Epub 2022 Oct 25. HLA. 2023. PMID: 36251018
Addressing these difficulties, we present a refined approach for characterizing presence or absence of HLA-A*02, the most common HLA-A allele in the Caucasian population, in archival samples. ...Overall, our method can help to promote studying HLA type …
Addressing these difficulties, we present a refined approach for characterizing presence or absence of HLA-A*02, the most comm …
Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Nature. 2023 Nov;623(7988):820-827. doi: 10.1038/s41586-023-06706-0. Epub 2023 Nov 8. Nature. 2023. PMID: 37938771 Free PMC article.
We focused on targeting the unmutated peptide QYNPIRTTF discovered on HLA-A*24:02, which is derived from the neuroblastoma-dependency gene and master transcriptional regulator PHOX2B. ...Informed by our computational modelling results, we show that PHOX2B PC-CARs al …
We focused on targeting the unmutated peptide QYNPIRTTF discovered on HLA-A*24:02, which is derived from the neuroblastoma-dep …
Tebentafusp: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4. Drugs. 2022. PMID: 35364798 Review.
Tebentafusp (tebentafusp-tebn; Kimmtrak()) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor (TCR) CD3 T cell engager being developed by Immunocore for the treatment of uveal melanoma and malignant melanoma. The TCR arm of tebentafus …
Tebentafusp (tebentafusp-tebn; Kimmtrak()) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor …
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, Ikeda H, Endo M, Kato K, Kitano S, Matsumine A, Nagata Y, Kageyama S, Shiraishi T, Yamada T, Horibe K, Takesako K, Miwa H, Watanabe T, Miyahara Y, Shiku H. Okumura S, et al. BMJ Open. 2022 Nov 14;12(11):e065109. doi: 10.1136/bmjopen-2022-065109. BMJ Open. 2022. PMID: 36375974 Free PMC article.
CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not only cell surface antigens but also intracellular antigens. We have developed a CAR-T-cell product that recognises the comple …
CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not …
5,214 results